The Steepest Patent Cliff in Order Big pharma companies focusing on anti-diabetic drugs are bracing themselves for the steepest patent cliff this decade. With Eli
EU Pharmaceutical Legislation Reform to Enable Quicker Access and Foster Innovation In April 2023, the EU commission’s proposal to revise the pharmaceutical legislation consisted of
U.S. FDA approval of BioLineRx’s APHEXDA™ (Motixafortide) in combination with Filgrastim (G-CSF) – a ray of hope for patients with Multiple Myeloma BioLineRx Ltd., a
Generics for Otezla® to be out in the United States in February 2028 Amgen’s oral phosphodiesterase-4 (PDE-4) inhibitor – Otezla® (Apremilast) is approved in the
Inflation Reduction Act: Patients sigh relief but confusion for biosimilar manufacturers The Inflation Reduction Act of 2022 (IRA) was signed into law in the United
First generic of Vyvanse® launched in the United States Vyvanse® (Lisdexamfetamine dimesylate), a schedule C-II controlled substance, was approved by the U.S. Food and Drug Administration
